How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,009 results for

Systemic Lupus Erythematosus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Septic shock among patients with systemic lupus erythematosus: Short and long-term outcome. Analysis of a French nationwide database. (PubMed)

Septic shock among patients with systemic lupus erythematosus: Short and long-term outcome. Analysis of a French nationwide database. We aimed to assess the characteristics, outcomes and costs of septic shock complicating Systemic Lupus Erythematosus (SLE).Characteristics of SLE patients experiencing a septic shock in France from 2010 to 2015 were analyzed through the French medico-administrative database. Factors associated with the 1-year post-admission mortality were analyzed, the crude 1

2019 Journal of Infection

142. Meta-analysis of associations of vascular endothelial growth factor protein levels and -634G/C polymorphism with systemic lupus erythematosus susceptibility. (PubMed)

Meta-analysis of associations of vascular endothelial growth factor protein levels and -634G/C polymorphism with systemic lupus erythematosus susceptibility. The purpose of this study was to detect the effects of vascular endothelial growth factor (VEGF) on systemic lupus erythematosus (SLE) risk.Associated studies were extracted from the China Biological Medicine Database (CBM), and PubMed on June 10, 2018, and applicable investigations were pooled and analyzed by meta-analysis using RevMan (...) 5.3.VEGF levels was associated with SLE risk (mean differences (MD) =196.02, 95% CI: 135.29-256.75, P < 0.00001), and VEGF levels was associated with active SLE risk (MD =77.51, 95% CI: 10.98-144.05, P = 0.02). We also found that VEGF levels was associated with SLE developing into lupus nephritis (LN) risk (MD =223.16, 95% CI: 144.38-301.93, P < 0.00001). However, VEGF -634G/C gene polymorphism (rs2010963) was not associated with SLE risk.VEGF levels was associated with SLE risk, active SLE risk

Full Text available with Trip Pro

2019 BMC Medical Genetics

143. Mindfulness-based cognitive therapy in Korean patients with systemic lupus erythematosus: A pilot study. (PubMed)

Mindfulness-based cognitive therapy in Korean patients with systemic lupus erythematosus: A pilot study. and purpose: The stress and systemic lupus erythematosus (SLE) are intertwined and affecting each other. This pilot study evaluated the mindfulness-based cognitive therapy (MBCT) in Korean patients with SLE.The Korean version of the Beck Depression Inventory-II (BDI-II), Beck Anxiety Inventory (BAI), Satisfaction with Life Scale (SWLS), and Perceived Stress Scale (PSS) were evaluated

2019 Complementary Therapies in Clinical Practice

144. Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. (PubMed)

Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. The presence of proinflammatory low-density granulocytes (LDG) has been demonstrated in autoimmune and infectious diseases. Recently, regulatory neutrophilic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) were identified in systemic lupus erythematosus (SLE). Because LDG and PMN-MDSC share a similar phenotype with contrasting functional effects, we explored

Full Text available with Trip Pro

2019 Annals of the Rheumatic Diseases

145. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. (PubMed)

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity and prevention of flares (...) . Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of GC. In persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab

Full Text available with Trip Pro

2019 Annals of the Rheumatic Diseases

146. Risk of severe herpes simplex virus infection in systemic lupus erythematosus: analysis of epidemiology and risk factors analysis in Taiwan. (PubMed)

Risk of severe herpes simplex virus infection in systemic lupus erythematosus: analysis of epidemiology and risk factors analysis in Taiwan. Patients with systemic lupus erythematosus (SLE) are susceptible to herpes simplex virus (HSV) infection, which occasionally leads to severe complications including meningoencephalitis and keratitis. However, few attempts to analyse the associated incidence and risk factors have been made.We enrolled patients with SLE recorded between 1997 and 2012

2019 Annals of the Rheumatic Diseases

147. Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes. (PubMed)

Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes. Cognitive dysfunction (CD) is common in systemic lupus erythematosus (SLE) but the cause remains unclear and treatment options are limited. We aimed to compare cognitive function in SLE and healthy controls (HCs) using both behavioural and neuroimaging techniques.Patients with SLE with stable disease and HCs were recruited. Clinical and psychological data

Full Text available with Trip Pro

2019 Annals of the Rheumatic Diseases

148. All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013). (PubMed)

All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013). Survival in systemic lupus erythematosus (SLE) has improved substantially in the last 50 years. The aim of the present study was to assess the evolution of the all-cause, cause-specific and age-specific standardised mortality ratios (SMRs) of patients with lupus in Ontario, Canada.Between 1971 and 2013, 1732 patients were followed (...) in the Toronto Lupus Clinic. Causes of death were retrieved from death certificates, autopsy reports, hospital records or the records of the family physicians. They were categorised as atherosclerotic, infectious, malignancy, active lupus and others. For the calculation of the SMR (indirect standardisation method), data from the general population of Ontario, Canada were used (Statistics Canada).Two hundred and forty-nine patients (205 women) died (infections 24.5%, atherosclerosis 15.7%, active lupus 13.3

2019 Annals of the Rheumatic Diseases

149. Construction of a frailty index as a novel health measure in systemic lupus erythematosus. (PubMed)

Construction of a frailty index as a novel health measure in systemic lupus erythematosus. To construct a frailty index (FI) as a measure of vulnerability to adverse outcomes among patients with SLE, using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.The SLICC inception cohort consists of recently diagnosed SLE patients followed annually with clinical and laboratory assessments. For this analysis, the baseline visit was defined as the first study

2019 Journal of Rheumatology

150. Echocardiographic Assessment of Diastolic Function in Children with Incident Systemic Lupus Erythematosus. (PubMed)

Echocardiographic Assessment of Diastolic Function in Children with Incident Systemic Lupus Erythematosus. The timing and etiology of diastolic impairment in pediatric-onset systemic lupus erythematosus (SLE) are poorly understood. We compared echocardiographic metrics of left ventricular diastolic function in children at SLE diagnosis to controls and identified factors associated with diastolic indices. Echocardiograms of children aged 5-18 years within 1 year of SLE diagnosis and age-/sex

2019 Pediatric Cardiology

151. Bacteremia in systemic lupus erythematosus patients from RELESSER: risk factors, clinical and microbiological characteristics and outcomes. (PubMed)

Bacteremia in systemic lupus erythematosus patients from RELESSER: risk factors, clinical and microbiological characteristics and outcomes. To describe the incidence of bacteremia in a large multicentric cohort of SLE patients and their clinical characteristics and to identify risk factors.All bacteremic episodes from the RELESSER registry were included. Clinical and laboratory characteristics concerning bacteremia and SLE status, as well as comorbidities at the time of infection, were

2019 Journal of Rheumatology

152. The burden of chronic kidney disease in systemic lupus erythematosus: A nationwide epidemiologic study. (PubMed)

The burden of chronic kidney disease in systemic lupus erythematosus: A nationwide epidemiologic study. To analyze the impact of chronic kidney disease (CKD) on major clinical outcome in SLE by using a nationwide database.Characteristics of all admitted SLE patients experiencing CKD (eGFR <60 mL/min/1.73 m2) in France from 2009 to 2015 were analyzed through the French medico- administrative database. Factors associated with CKD and major clinical outcomes such as end-stage renal disease (ESRD (...) ), cardiovascular event (CVE), septic shock and death were assessed. We used a multivariate Cox proportional hazard model and subdistribution hazard models to analyze survival without major clinical events according to the presence of CKD.From 2009 to 2015, 26,320 SLE patients were hospitalized in France. Among them, 6439 (86.5% women; mean age 45.7 [16.5] years old) had a baseline stay in 2009 during which CKD was reported in 428 (6.7%) cases. Multivariate analysis showed that lupus nephritis (OR 6.6 [5.2-8.4

2019 Autoimmunity reviews

153. Pseudo-pseudo Meigs' syndrome presenting with a combination of polyserositis, elevated serum CA 125 in systemic lupus erythematosus: A case report. (PubMed)

Pseudo-pseudo Meigs' syndrome presenting with a combination of polyserositis, elevated serum CA 125 in systemic lupus erythematosus: A case report. Combination of polyserositis and elevated serum CA 125 is common in tumor or infectious disease, but this clinical combination is also found in other diseases. It could be the initial manifestation of pseudo-pseudo Meigs' syndrome (PPMS), which is characterized by the presence of polyserositis and raised CA-125 level in systemic lupus erythematosus

Full Text available with Trip Pro

2019 Medicine

154. A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report. (PubMed)

A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report. Gain of function (GOF) mutations in PIK3CD gene encoding PI3K p110δ were recently associated with a novel combined immune deficiency characterized by recurrent sinopulmonary infections, CD4 lymphopenia, reduced class-switched memory B cells, lymphadenopathy, cytomegalovirus and/or epstein-Barr virus (EBV) viremia, and EBV-related lymphoma. A subset of affected patients also had elevated serum IgM.We report (...) a patient who was diagnosed with systemic lupus erythematosus (SLE) at a young age and was recently found to carry heterozygous mutations in PIK3CD. The patient not only presented with recurrent sinopulmonary infections, CD4 lymphopenia, lymphadenopathy, EBV viremia, and elevated serum IgM, but also met classification criteria of SLE based on persistent proteinuria and hematuria, leukopenia and anemia, low level of serum complement, and positive autoantibody for antinuclear antibodies.Activated PI3Kδ

Full Text available with Trip Pro

2019 Medicine

155. Incomplete systemic lupus erythematosus - what remains after application of ACR and SLICC criteria? (PubMed)

Incomplete systemic lupus erythematosus - what remains after application of ACR and SLICC criteria? Incomplete systemic lupus erythematosus (iSLE) is an acknowledged condition of patients with clinical signs of lupus who do not fulfill classification criteria for SLE. Some iSLE patients have persistent mild disease, but others have serious organ involvement, and up to 55% progress to established SLE. Research on this subject could reveal predictive or diagnostic biomarkers for SLE. Ideally (...) , it would become possible to discriminate those patients with critical organ involvement or a high risk for progression to SLE. This "high risk" group might benefit from early treatment, which would preferably be confirmed in randomized controlled trials. However, this requires agreement on a definition of iSLE. The Systemic Lupus International Collaborating Clinics (SLICC) classification criteria was composed in order to diagnose SLE earlier. This review outlines the clinical characteristics of iSLE

Full Text available with Trip Pro

2019 Arthritis care & research

156. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. (PubMed)

Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Glucocorticoids are potent anti-inflammatory and immunosuppressant medications and remain the mainstay of systemic lupus erythematosus (SLE) therapy. The potency of a specific glucocorticoid, i.e., the dose of glucocorticoid that is required to produce a specific effect, is dependent on its pharmacokinetic (PK) and pharmacodynamic (PD) properties. In this review, we summarize

2019 Seminars in arthritis and rheumatism

157. Metabolism as a key regulator in the pathogenesis of systemic lupus erythematosus. (PubMed)

Metabolism as a key regulator in the pathogenesis of systemic lupus erythematosus. In the middle of the 20th century, biologists focused on investigating the mechanism of gene regulation and signal transduction in cells, which led to the concept that metabolites were products of gene expression and signal transduction pathways. In the 1920s, the importance of cellular metabolism was shown in the Warburg effect, in which cancer cells are characterized by a mitochondrial defect that shifts (...) (OXPHOS) and fatty acid oxidation (FAO), whereas activated lymphocytes rapidly shift to the glycolytic pathway. A detailed understanding of metabolic regulation has progressed rapidly, especially in T cells during their differentiation from naïve to effector T cells. Metabolism is now considered to play a key role in autoimmune diseases. Metabolic changes in autoimmune diseases might be due to inflammation as well as being involved in autoimmune pathogenesis. Systemic lupus erythematosus (SLE

2019 Seminars in arthritis and rheumatism

158. Assessment of the psychometric properties of patient-reported outcomes of depression and anxiety in systemic lupus erythematosus. (PubMed)

Assessment of the psychometric properties of patient-reported outcomes of depression and anxiety in systemic lupus erythematosus. This study aimed to: 1) determine the prevalence of depression and anxiety in SLE patients using the Center for Epidemiological Studies-Depression Scale [CES-D], Hospital Anxiety and Depression Scale [HADS], and Beck Anxiety Inventory [BAI] questionnaires; 2) study the criterion validity, interpretability, and test-retest reliability of CES-D, HADS and BAI; and 3

2019 Seminars in arthritis and rheumatism

159. Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis. (PubMed)

Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis. Dyslipidemia is a common disorder in systemic lupus erythematosus (SLE) patients. It is still inconclusive whether antimalarial drugs could affect the serum lipids in SLE patients, therefore we conducted a systematic review and meta-analysis of available data to address this issue.We comprehensively searched the databases of PubMed, EMBASE and Cochrane Library from

Full Text available with Trip Pro

2019 Medicine

160. An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. (PubMed)

An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. Neutrophils derive from hematopoietic stem cells (HSCs) with systemic inflammation driving their activation and differentiation to myeloid progenitors to ensure enhanced myelopoiesis. Epigenetic reprograming and re-education of these HSCs produces neutrophils primed towards elimination (...) may not be present in chronic inflammatory lesions, their remnants may amplify the inflammatory response beyond their short life-span in the tissues. Herein, we review current evidence supporting a role of neutrophils and NETosis in tissue injury and dysfunction in systemic autoimmunity using as disease paradigms Systemic Lupus Erythematosus (SLE) and the ANCA-associated vasculitides (AAV). We also discuss the mechanisms involved and their potential as targets for novel therapy and drug

2019 Autoimmunity reviews

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>